Concepts (204)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| DNA Methylation | 19 | 2026 | 403 | 4.530 |
Why?
|
| Prostatic Neoplasms | 28 | 2026 | 1092 | 4.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 13 | 2026 | 968 | 2.580 |
Why?
|
| Epigenesis, Genetic | 5 | 2026 | 291 | 1.570 |
Why?
|
| Homeodomain Proteins | 2 | 2026 | 150 | 1.190 |
Why?
|
| Prostate | 8 | 2023 | 155 | 0.890 |
Why?
|
| Trans-Activators | 1 | 2026 | 192 | 0.880 |
Why?
|
| Histone-Lysine N-Methyltransferase | 2 | 2023 | 31 | 0.850 |
Why?
|
| Crocus | 1 | 2023 | 21 | 0.810 |
Why?
|
| Phosphoproteins | 3 | 2011 | 206 | 0.760 |
Why?
|
| Membrane Proteins | 5 | 2012 | 561 | 0.740 |
Why?
|
| Biological Products | 1 | 2023 | 91 | 0.730 |
Why?
|
| Hydrocortisone | 1 | 2022 | 93 | 0.710 |
Why?
|
| Promoter Regions, Genetic | 9 | 2025 | 526 | 0.700 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2020 | 8 | 0.650 |
Why?
|
| Cell Line, Tumor | 13 | 2026 | 2676 | 0.640 |
Why?
|
| Androgens | 1 | 2020 | 106 | 0.610 |
Why?
|
| CpG Islands | 8 | 2023 | 109 | 0.590 |
Why?
|
| Male | 31 | 2026 | 23409 | 0.580 |
Why?
|
| Tumor Suppressor Proteins | 5 | 2025 | 223 | 0.540 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2016 | 55 | 0.480 |
Why?
|
| Cytokines | 2 | 2018 | 678 | 0.480 |
Why?
|
| Fibroblast Growth Factors | 6 | 2006 | 36 | 0.470 |
Why?
|
| Humans | 36 | 2026 | 43102 | 0.470 |
Why?
|
| Receptors, Fibroblast Growth Factor | 4 | 2004 | 11 | 0.460 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 2 | 2013 | 13 | 0.440 |
Why?
|
| Gene Silencing | 4 | 2011 | 154 | 0.430 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 590 | 0.420 |
Why?
|
| Gene Expression Profiling | 3 | 2023 | 704 | 0.380 |
Why?
|
| Nerve Tissue Proteins | 2 | 2023 | 386 | 0.370 |
Why?
|
| RNA, Messenger | 6 | 2023 | 1271 | 0.340 |
Why?
|
| Transcription Factors | 3 | 2011 | 735 | 0.340 |
Why?
|
| Phosphoric Monoester Hydrolases | 2 | 2001 | 35 | 0.340 |
Why?
|
| Inflammation | 1 | 2016 | 758 | 0.330 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2001 | 61 | 0.330 |
Why?
|
| DNA-Binding Proteins | 4 | 2023 | 561 | 0.330 |
Why?
|
| Genes | 1 | 2010 | 56 | 0.330 |
Why?
|
| Receptors, Retinoic Acid | 3 | 2018 | 27 | 0.320 |
Why?
|
| Breast Neoplasms | 4 | 2025 | 1723 | 0.300 |
Why?
|
| Sequence Analysis, DNA | 5 | 2013 | 515 | 0.290 |
Why?
|
| Transcription, Genetic | 1 | 2011 | 592 | 0.280 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 8 | 2010 | 652 | 0.260 |
Why?
|
| Cell Movement | 3 | 2026 | 655 | 0.240 |
Why?
|
| Case-Control Studies | 2 | 2019 | 1285 | 0.230 |
Why?
|
| Alternative Splicing | 2 | 2009 | 94 | 0.230 |
Why?
|
| Adult | 8 | 2025 | 13872 | 0.230 |
Why?
|
| Aged | 6 | 2019 | 8214 | 0.230 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-3 | 2 | 2018 | 9 | 0.230 |
Why?
|
| Azacitidine | 2 | 2016 | 21 | 0.230 |
Why?
|
| Fibroadenoma | 1 | 2025 | 4 | 0.230 |
Why?
|
| Osteonectin | 2 | 2018 | 10 | 0.230 |
Why?
|
| Cadherins | 2 | 2018 | 102 | 0.220 |
Why?
|
| Receptors, Androgen | 2 | 2020 | 144 | 0.220 |
Why?
|
| Middle Aged | 7 | 2025 | 12222 | 0.210 |
Why?
|
| Estrogen Receptor alpha | 1 | 2025 | 121 | 0.210 |
Why?
|
| Disease Progression | 6 | 2025 | 667 | 0.210 |
Why?
|
| Histocompatibility Antigens | 1 | 2023 | 12 | 0.210 |
Why?
|
| Emetine | 2 | 2015 | 14 | 0.210 |
Why?
|
| Metabolic Diseases | 1 | 2023 | 40 | 0.200 |
Why?
|
| Administration, Oral | 1 | 2023 | 260 | 0.200 |
Why?
|
| Fatty Liver | 1 | 2023 | 77 | 0.190 |
Why?
|
| Immunoglobulin A | 1 | 2022 | 65 | 0.190 |
Why?
|
| Adolescent | 3 | 2022 | 6081 | 0.180 |
Why?
|
| Cell Proliferation | 3 | 2026 | 1455 | 0.180 |
Why?
|
| Tumor Cells, Cultured | 5 | 2016 | 508 | 0.180 |
Why?
|
| Gene Expression Regulation | 1 | 2007 | 1070 | 0.180 |
Why?
|
| Aging | 1 | 2007 | 783 | 0.180 |
Why?
|
| Carrier Proteins | 1 | 2023 | 321 | 0.180 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2023 | 384 | 0.180 |
Why?
|
| Saliva | 1 | 2022 | 119 | 0.170 |
Why?
|
| Glutathione S-Transferase pi | 2 | 2011 | 10 | 0.170 |
Why?
|
| Immunoglobulin G | 1 | 2022 | 259 | 0.170 |
Why?
|
| Young Adult | 3 | 2022 | 5080 | 0.170 |
Why?
|
| Liver Neoplasms | 1 | 2023 | 224 | 0.170 |
Why?
|
| Sex Characteristics | 1 | 2022 | 258 | 0.160 |
Why?
|
| Pseudogenes | 1 | 2000 | 12 | 0.160 |
Why?
|
| Mice | 7 | 2023 | 6644 | 0.160 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2001 | 139 | 0.160 |
Why?
|
| DNA | 2 | 2022 | 592 | 0.160 |
Why?
|
| Prognosis | 2 | 2019 | 861 | 0.150 |
Why?
|
| Polymerase Chain Reaction | 2 | 2016 | 455 | 0.150 |
Why?
|
| Genetic Markers | 1 | 2018 | 150 | 0.140 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2018 | 83 | 0.140 |
Why?
|
| Interleukin-5 | 1 | 2016 | 6 | 0.130 |
Why?
|
| Chemokine CXCL5 | 1 | 2016 | 5 | 0.130 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 1067 | 0.130 |
Why?
|
| Vitamin D | 1 | 2018 | 196 | 0.120 |
Why?
|
| Hydroxamic Acids | 1 | 2016 | 33 | 0.120 |
Why?
|
| Tissue Array Analysis | 1 | 2016 | 80 | 0.120 |
Why?
|
| Epithelial Cells | 4 | 2010 | 434 | 0.120 |
Why?
|
| DNA Primers | 2 | 2007 | 294 | 0.120 |
Why?
|
| Chemokines, CC | 1 | 2016 | 55 | 0.120 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2013 | 25 | 0.110 |
Why?
|
| Drug Design | 2 | 2015 | 186 | 0.110 |
Why?
|
| Female | 9 | 2025 | 24698 | 0.110 |
Why?
|
| Child | 1 | 2022 | 3443 | 0.110 |
Why?
|
| Transfection | 2 | 2006 | 532 | 0.100 |
Why?
|
| Animals | 7 | 2023 | 16992 | 0.100 |
Why?
|
| Fibroblast Growth Factor 2 | 2 | 2004 | 45 | 0.100 |
Why?
|
| Glomerular Filtration Rate | 1 | 2014 | 147 | 0.100 |
Why?
|
| Cluster Analysis | 1 | 2013 | 207 | 0.100 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 2853 | 0.100 |
Why?
|
| DNA Mutational Analysis | 2 | 2004 | 95 | 0.090 |
Why?
|
| Binding Sites | 2 | 2011 | 671 | 0.090 |
Why?
|
| Molecular Sequence Data | 3 | 2011 | 1542 | 0.090 |
Why?
|
| Acetaminophen | 1 | 2011 | 30 | 0.090 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2012 | 100 | 0.090 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2012 | 388 | 0.090 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2014 | 193 | 0.080 |
Why?
|
| Sequence Alignment | 1 | 2011 | 272 | 0.080 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2001 | 59 | 0.080 |
Why?
|
| Base Sequence | 2 | 2011 | 983 | 0.080 |
Why?
|
| Health | 1 | 2010 | 30 | 0.080 |
Why?
|
| Risk Factors | 1 | 2018 | 3994 | 0.080 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 1081 | 0.080 |
Why?
|
| Homozygote | 1 | 2009 | 77 | 0.070 |
Why?
|
| Models, Genetic | 1 | 2009 | 183 | 0.070 |
Why?
|
| Gene Deletion | 1 | 2009 | 168 | 0.070 |
Why?
|
| Liver | 1 | 2011 | 511 | 0.070 |
Why?
|
| Lysine | 1 | 2008 | 119 | 0.070 |
Why?
|
| Up-Regulation | 3 | 2004 | 536 | 0.070 |
Why?
|
| Relaxin | 1 | 2007 | 10 | 0.070 |
Why?
|
| Histones | 1 | 2008 | 197 | 0.060 |
Why?
|
| In Situ Hybridization | 1 | 2006 | 138 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2005 | 7 | 0.060 |
Why?
|
| Regression Analysis | 1 | 2007 | 490 | 0.060 |
Why?
|
| Genomic Imprinting | 1 | 2005 | 35 | 0.060 |
Why?
|
| MicroRNAs | 1 | 2011 | 518 | 0.060 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 200 | 0.060 |
Why?
|
| Proteoglycans | 1 | 2004 | 49 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2004 | 934 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2007 | 291 | 0.050 |
Why?
|
| Prostatic Hyperplasia | 1 | 2004 | 32 | 0.050 |
Why?
|
| Thymidylate Synthase | 1 | 2003 | 2 | 0.050 |
Why?
|
| Methionine | 1 | 2003 | 27 | 0.050 |
Why?
|
| Repressor Proteins | 1 | 2005 | 273 | 0.050 |
Why?
|
| Proteins | 1 | 2005 | 382 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2008 | 495 | 0.050 |
Why?
|
| Mice, Knockout | 2 | 2003 | 1035 | 0.040 |
Why?
|
| Cell Division | 4 | 2004 | 311 | 0.040 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2001 | 3 | 0.040 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2001 | 3 | 0.040 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2001 | 29 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2023 | 760 | 0.040 |
Why?
|
| Survival Rate | 1 | 2001 | 355 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2001 | 139 | 0.040 |
Why?
|
| Blotting, Southern | 1 | 2000 | 68 | 0.040 |
Why?
|
| Carbon | 1 | 2021 | 128 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2000 | 257 | 0.040 |
Why?
|
| Neoplasms | 1 | 2008 | 1377 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2004 | 1019 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2004 | 2157 | 0.030 |
Why?
|
| Translocation, Genetic | 1 | 1995 | 40 | 0.030 |
Why?
|
| Genetic Engineering | 1 | 1995 | 37 | 0.030 |
Why?
|
| Recombination, Genetic | 1 | 1995 | 95 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2015 | 506 | 0.030 |
Why?
|
| Alleles | 2 | 2005 | 352 | 0.030 |
Why?
|
| Hydrolysis | 1 | 2012 | 97 | 0.020 |
Why?
|
| Obesity | 1 | 2021 | 1151 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2012 | 99 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2011 | 1596 | 0.020 |
Why?
|
| Biocatalysis | 1 | 2011 | 30 | 0.020 |
Why?
|
| Stromal Cells | 2 | 2000 | 55 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2007 | 1869 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 2000 | 518 | 0.020 |
Why?
|
| Colony-Forming Units Assay | 1 | 2008 | 9 | 0.020 |
Why?
|
| Genes, Neoplasm | 1 | 2008 | 14 | 0.020 |
Why?
|
| Clone Cells | 1 | 2008 | 50 | 0.020 |
Why?
|
| Alkaline Phosphatase | 1 | 2008 | 54 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2008 | 64 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2008 | 74 | 0.020 |
Why?
|
| Acetylation | 1 | 2008 | 107 | 0.020 |
Why?
|
| Microfilament Proteins | 1 | 2008 | 72 | 0.020 |
Why?
|
| Receptors, Peptide | 1 | 2007 | 24 | 0.020 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2007 | 93 | 0.020 |
Why?
|
| Uniparental Disomy | 1 | 2005 | 3 | 0.020 |
Why?
|
| Consensus Sequence | 1 | 2005 | 21 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2007 | 368 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2008 | 223 | 0.010 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2005 | 49 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2007 | 665 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2008 | 1621 | 0.010 |
Why?
|
| Fibroblast Growth Factor 1 | 1 | 2003 | 4 | 0.010 |
Why?
|
| Nucleotides | 1 | 2003 | 37 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2004 | 152 | 0.010 |
Why?
|
| Folic Acid | 1 | 2003 | 49 | 0.010 |
Why?
|
| Fluorouracil | 1 | 2003 | 47 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2003 | 183 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2003 | 310 | 0.010 |
Why?
|
| Fibroblast Growth Factor 10 | 1 | 2000 | 1 | 0.010 |
Why?
|
| Mitogens | 1 | 2000 | 10 | 0.010 |
Why?
|
| Fibroblast Growth Factor 6 | 1 | 2000 | 1 | 0.010 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 4 | 1 | 2000 | 2 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2003 | 638 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2000 | 458 | 0.010 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 1 | 1995 | 12 | 0.010 |
Why?
|
| Genes, myc | 1 | 1995 | 31 | 0.010 |
Why?
|
| Genes, Immunoglobulin | 1 | 1995 | 37 | 0.010 |
Why?
|
| Gene Targeting | 1 | 1995 | 39 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 1995 | 58 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 1995 | 165 | 0.010 |
Why?
|
| Plasmids | 1 | 1995 | 244 | 0.010 |
Why?
|
| Stem Cells | 1 | 1995 | 152 | 0.010 |
Why?
|
| Cell Line | 1 | 1995 | 1410 | 0.010 |
Why?
|